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Background: The mitochondrial m.1555A>G mutation is associated with a high rate of permanent hearing loss, if
aminoglycosides are given. Preterm infants have an increased risk of permanent hearing loss and are frequently
treated with aminoglycoside antibiotics.
Methods: We genotyped preterm infants with a birth weight below 1500 grams who were prospectively enrolled
in a large cohort study for the m.1555A>G mutation. Treatment with aminoglycoside antibiotics in combination
with mitochondrial m.1555A>G mutation was tested as a predictor for failed hearing screening at discharge in a
multivariate logistic regression analysis.
Results: 7056 infants were genotyped and analysed. Low birth weight was the most significant predictor of failed
hearing screening (p = 7.3 × 10−10). 12 infants (0.2%) had the m.1555A>G-mutation. In a multivariable logistic
regression analysis, the combination of aminoglycoside treatment with m.1555A>G-carrier status was associated
with failed hearing screening (p = 0.0058). However, only 3 out of 10 preterm m.1555A>G-carriers who were
exposed to aminoglycosides failed hearing screening. The m.1555A>G-mutation was detected in all mothers of
m.1555A>G-positive children, but in none of 2993 maternal DNA-samples of m.1555A>G-negative infants.
Conclusion: Antenatal screening for the m.1555A>G mutation by maternal genotyping of pregnant women with
preterm labour might be a reasonable approach to identify infants who are at increased risk for permanent hearing
loss. Additional studies are needed to estimate the relevance of cofactors like aminoglycoside plasma levels and
birth weight and the amount of preterm m.1555A>G-carriers with permanent hearing loss.
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In 1993 a maternally transmitted non-syndromic deaf-
ness with susceptibility to aminoglycoside treatment was
reported to be due to a single nucleotide (A to G) substi-
tution at position 1555 of the mitochondrial genome [1].
The variant m.1555A>G genotype is found about 1 in
500 Europeans [2]. Subsequent studies showed that the
effect of this mutation is observed, even when aminogly-
coside levels are within the therapeutic range [3,4]. The* Correspondence: wolfgang.goepel@uksh.de
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unless otherwise stated.m.1555A>G-mutation is frequently found in families
with maternally transmitted hearing loss. In these fam-
ilies, all carriers of the mutation who received aminogly-
cosides became deaf [5]. However, in population based
cohort studies hearing in children and adults carrying
the mutation was not impaired [2,6].
The role of the m.1555A>G mutation has not been
investigated in populations with high aminoglycoside
treatment rates and routine hearing tests. We therefore
screened a large cohort of preterm infants with a birth
weight below 1500 grams for the m.1555A>G muta-
tion to test, if established risk factors for congential
hearing impairment and m.1555A>G in combinationtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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failure rate of newborn hearing screening. We furthermore
screened a large number of mothers of these infants to
determine if maternal genetic screening for m.1555A>G
would be feasible in order to prevent postnatal aminogly-
coside treatment of infants carrying the mutation.
Methods
Study population
The German Neonatal Network (GNN) is a prospective
multicentre cohort study of preterm infants with a birth
weight below 1500 grams which is supported by the
German Federal Ministry of Research and Education.
Improvement of the long term outcome of preterm infants
is the major aim of the GNN. Some additional information
is given at www.vlbw.de. We analysed infants with a gesta-
tional age below 37 + 0 weeks and a birth weight less than
1500 grams and their mothers who were enrolled from 46
German neonatal intensive care units between 2003 and
2012. Antenatal and postnatal clinical data were docu-
mented on standardised data sheets during the hospital
course of the patients. Data quality was ensured by regular
on-site-monitoring done by physicians of the central office
of the German Neonatal Network at the University of
Lübeck. Clinical data were coded and entered into a central
database. Results of newborn hearing screening were col-
lected during the whole study. Written informed consent
for sample and data collection was given by parents of all
participating infants. The study was approved by the ethics
committee of the University of Lübeck and by ethics com-
mittees of all participating hospitals and universities.
Outcomes and exposures
According to a recent review on risk factors for hearing
loss in very low birth weight infants [7] and a report on
vancomycin ototoxicity in neonates [8], we defined birth
weight, bronchopulmonary dysplasia (BPD, defined as need
for oxygen supplementation at 36 weeks post-menstrual
gestational age) and treatment with furosemide, gly-
copeptide antibiotics or ganciclovir/valganciclovir as risk
factors for failed newborn hearing screening. We used
gancyclovir/valgancyclovir treatment as a marker for
congenital cytomegalovirus (CMV) infection since this is
the only indication for gancyclovir treatment of preterm
infants. The m.1555A>G genotype in combination with
documented aminoglycoside treatment was analyzed as a
risk factor for failed neonatal hearing screening. Neonatal
hearing screening was performed using otoacoustic emis-
sions, usually before discharge of the infant, but some cen-
tres used brainstem evoked response audiometry.
Genotyping
DNA was collected by buccal swabs (mothers and infants)
or umbilical cord tissue (infants). DNA was extracted bystandard procedures (Qiagen blood and tissue kits,
Germany) and stored at −20 degrees centigrade at the
University of Lübeck. DNA-samples of infants who were
born between 2003 and 2012 and were available at
our lab on December 31st 2012 were genotyped for
m.1555A>G. We used a custom assay (TaqMan-assay,
forward primer GACATTTAACTAAACCCTACGCATT,
reverse primer GTCCAAGTGCACTTTCCAGTACA
reporter ATGTTACGACTTGTCTCCTC / ACGACTTG
CCTCCTC) for allelic discrimination with a HT7900
thermocycler (Applied Biosystems, California, USA).
Maternal samples were genotyped for infants carrying the
m.1555A>G-genotype and additional maternal samples of
infants who had no m.1555A>G-mutation.
Statistical methods
Statistical analysis was done with SPSS Version 20 (IBM,
New York, USA), by using a logistic regression modell
with failed newborn hearing screening as the dependent
and birth weight (100 g – increments), any treatment
with glycopeptide antibiotics, any treatment with fur-
osemide, CMV-infection, bronchopulmonary dysplasia
and aminoglycoside treatment × m.1555A>G-genotype
as independent variables. The global significance level
was set to 0.05. Adjustments for multiple testing were
done by Bonferroni correction for multiple comparisons
with 7 independent variables, and the nominal p-value
thus was 0.007. All p-values are two-sided. Data are re-
ported according to STROBE statement [9].
Results
DNA-samples of 8504 infants were available. Infants
without neonatal hearing screening (n = 892, 10.5%), or
missing data for confounding variables (n = 143, 1.7%)
were excluded. 412 infants were excluded because of
failed m.1555A>G-genotyping and one infant because of
suspected DNA-contamination with a positive control
(total n = 413 infants, 4.9%). 7056 infants were finally
included in our analysis.
3554 infants were male (50.4%) and 2357 infants (33.4%)
were multiples. Clinical data and results of the multivariate
logistic regression analysis are given in Table 1. Low birth
weight was the most important predictor of failed hearing
screening (OR 0.91, 95%CI 0.88-0.94 per 100 g additional
birth weight, Figure 1).
12 infants (0.2%) carried the m.1555A>G-mutation.
Only 2 of these infants were not treated with aminogly-
coside antibiotics like gentamicin or tobramycine. Both
had normal newborn hearing screening. Three of ten
m.1555A>G carriers, who were treated with aminoglyco-
sides failed newborn hearing screening. The combination
of aminoglycoside treatment × m.1555A>G-genotype
was a significant predictor of failure (OR 1.26, 95% CI
1.07-1.49, p = 0.0058). If aminoglycoside treatment and
Table 1 Failed neonatal hearing screening: multivariate logistic regression of risk factors
Failed neonatal hearing screening
[% (n failed hearing screening/n
with risk factor)
OR 95% CI p
All 11% (788/7056) Ref.
Birth weight# 0.91 0.88-0.94 7.3 × 10−10*
No Aminoglycosides, m.1555A>G - 8.5% (224/2636) 1.26 1.07-1.49 0.0058*
No Aminoglycosides m.1555A>G + 0% (0/2)
Aminoglycosides m.1555A>G - 12.7% (561/4408)
Aminoglycosides m.1555A>G + 30% (3/10)
Vancomycin treatment 15.8% (349/2208) 1.24 1.04-1.47 0.015
Furosemide treatment 17.6% (238/1355) 1.29 1.08-1.57 0.0066*
Cytomegalovirus-infection 27% (6/22) 1.80 0.69-4.7 0.23
Infants with BPD 18.6% (195/1048) 1.21 0.99-1.49 0.067
#OR for birth weight is given per 100 g increased weight. Percentage of failed hearing screening for each category is given in Figure 1. *p < 0.007, multivariate
logistic regression.
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factors in the same multivariate logistic regression model,
none of them was predictive for failed hearing screening
(data not shown). Furosemide treatment was associated
with failed hearing screening as well, whereas other factors
such as vancomycin treatment, cytomegalovirus-infection
and BPD were not predictive. To test if other potentially
important confounders are associated with hearing loss, we
added sepsis (confirmed by positive blood-culture) and ab-
normal head scans (intra-ventricular haemorrhage detected
by ultrasound) to our multivariate logistic regression
model. However, both variables were not predictive for
failed hearing screening (sepsis: OR 0.97, 95% CI: 0.78-1.2;Figure 1 Failed newborn hearing screening as a function of birth wei
other strata include > 100 infants.p = 0.8; intra-ventricular haemorrhage: OR 0.94, 95% CI:
0.77-1.15, p = 0.5).
Additional clinical data of infants carrying the
m.1555A>G-mutation are given in Table 2. Six out of
twelve infants were monozygotic twin pairs. Remarkably,
two twin pairs who carried the mutation had discordant
hearing screening, with pathological results in the smaller
infant. Genotyping of maternal DNA was successful in
3002 of 3070 samples (97.7%). The m.1555A>G-mutation
was found in all 9 mothers whose infants also carried the
m.1555A>G-mutation (3 twin-mothers and 6 singleton
mothers). All other maternal samples were negative for
m.1555A>G.ght (n = 7056). The number of infants in the < 400 g strata is 39. All









1 1100-1199 28 M Y Y Pass
2 1100-1199 28 M Y Y Pass
3 800-899 25 F N Y Pass
4 1200-1299 29 M N N Pass
5 1200-1299 32 F N N Pass
6 1200-1299 29 F Y Y Pass
7 800-899 29 F Y Y Fail
8 1400-1499 32 M N Y Pass
9 1300-1399 30 M N Y Pass
10 1400-1499 30 F Y Y Pass
11 1300-1399 30 F Y Y Fail
12 <400 24 M N Y Fail
Birth weight and gestational age are given as completed 100 grams/completed weeks, respectively. All aminoglycoside treated infants received gentamicin.
Patients 1 and 2, 6 and 7 and patients 10 and 11 were twin pairs. None of the patients was treated with furosemide.
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Aminoglycoside treatment is standard of care for suspected
sepsis in newborns. Analysis of large scale epidemiological
data indicate, that substitution of aminoglycosides with
broad spectrum antibiotics such as cephalosporins as first
line treatment of newborn sepsis is associated with an in-
creased rate of death [10,11]. Therefore, general avoidance
of aminoglycoside treatment of newborns may not be feas-
ible or reasonable. However, it might be beneficial to
change aminoglycoside treatment in some selected patients
with a high risk of side effects, such as carriers of the
m.1555A>G-mutation. Ealy et al. screened 703 neonatal in-
tensive care unit patients and identified two m.1555A>G
carriers who were both treated with gentamicin and had
normal newborn hearing screening. These infants had a
gestational age of 33 and 34 weeks, respectively. Birth
weight was not reported [12]. Johnson et al. screened 436
infants and identified 3 infants with m.1555A>G who were
treated with gentamicin. One of these infants had repeat-
edly abnormal hearing tests [13]. Taken together, these
studies indicate, that about 20% (one of five) infants who
are carriers of m.1555A>G and received aminoglycosides
had abnormal hearing screening. In our study this rate was
even higher (3 of 10 infants), and comparable to the failure
rate of infants with CMV-infection which is an established
risk factor for permanent hearing loss.
Other risk factors which were included in our analysis
were associated with an increased risk of failed neonatal
hearing screening as well. Low birth weight itself was the
most important predictor, but all other reported risk fac-
tors were associated with higher failure rates of newborn
hearing screening, with significant p-values for treatment
with furosemide. As reversible hearing loss after furosem-
ide treatment is well described, this observation might beof minor importance for current treatment [7]. However,
since many preterm infants are treated with more than one
ototoxic drug simultaneously, ongoing cohort studies and
randomised trials involving aminoglycosides, vancomycin
and furosemide should consider the combined effect of
these drugs on permanent hearing loss.
Although we screened more than 7000 preterm in-
fants, the total number of m.1555A>G carriers in our
study was low, which limits the statistical power of our
observation. The rate of failed hearing screening in our
cohort was 11%, which is close to reported data in the
literature [14]. It is important to note, that most infants
with failed newborn hearing screening do not develop
permanent hearing loss.
However, family studies of m.1555A>G carriers indi-
cate a very high penetrance of permanent hearing loss if
aminoglycosides are given [5], and a recently published
follow up study including 19 Finish m.1555A>G carriers
reported that all children passed the newborn hearing
screening, but 10 of 19 developed permanent hearing
loss at a median age of 3.7 years [15]. Therefore, our
current data might considerably underestimate the long
term effect of the aminoglycoside use in preterm infants
carrying m.1555A>G.
5-year follow-up for GNN-infants who were enrolled
in 2009 or later will start in 2014. Since measurement of
evoked otoacoustic emissions are part of the follow-up,
we will be able to analyse more data concerning the
long-term effects of aminoglycoside treatment of pre-
term m.1555A>G carriers within the next years.
Conclusions
In this large cohort study of preterm infants with a birth
weight below 1500 grams, frequency of the m.1555A>G
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was associated with failed hearing screening at discharge
if carriers were treated with aminoglycoside antibiotics.
We found the mutation in all mothers of m.1555A>G-
carriers. It is reassuring that large cohort studies in
children and adults report normal hearing of m.1555A>G-
carriers if they were not treated with aminoglycosides
[2,6]. A British expert group recently suggested to screen
all pregnant women for m.1555A>G to prevent aminogly-
coside induced hearing loss in affected children [16]. Our
data support such an approach – at least in women with
preterm labour. However, it should be taken into account,
that empiric aminoglycoside treatment of newborns and
preterm infants with suspected sepsis is an extremely
valuable treatment strategy and such screening programs
should be carefully designed to avoid unwarranted re-
placement of established treatment schedules which in-
clude aminoglycoside antibiotics.
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